Cargando…
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors
Long-term treatment outcomes for patients with high grade ovarian cancers have not changed despite innovations in therapies. There is no recommended assay for predicting patient response to second-line therapy, thus clinicians must make treatment decisions based on each individual patient. Patient-d...
Autores principales: | Cotler, Max J., Ramadi, Khalil B., Hou, Xiaonan, Christodoulopoulos, Elena, Ahn, Sebastian, Bashyam, Ashvin, Ding, Huiming, Larson, Melissa, Oberg, Ann L., Whittaker, Charles, Jonas, Oliver, Kaufmann, Scott H., Weroha, S. John, Cima, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136609/ https://www.ncbi.nlm.nih.gov/pubmed/35472731 http://dx.doi.org/10.1016/j.tranon.2022.101427 |
Ejemplares similares
-
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting
por: Oberg, Ann L., et al.
Publicado: (2021) -
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022) -
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer
por: Kanakkanthara, Arun, et al.
Publicado: (2019) -
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A
por: Torres, Diogo, et al.
Publicado: (2019) -
CHFR and Paclitaxel Sensitivity of Ovarian Cancer
por: Wahner Hendrickson, Andrea E., et al.
Publicado: (2021)